NOTE
🌱 created from: gastric cancer
mgc1l
- ESOPEC demonstrated a superior EFS and OS of FLOT over FOFOX.
- No data now regarding using adjuvant Nivolumab +/- Ipilimumab.
- For mG/EGJ cancer without biomarkers, ARMANI study showed superior PFS and OS by early switch to ramucirumab + paclitaxel.
- RENAISSANCE study demonstrated that radical surgery for limited metastases did not improve OS for mG/EGJ cancer.
- Novel agents emerged quickly to provide GC patients with better survivals.
- EDGE study:promising activity of anti-TIGT plus anti-PD1 in first-line treatment for mG/EGJ cancer. Claudin 18.2 ADC showed promising activity in late line.
- RENASISANCE_Gastric
- ARMANI phase III
- NIVOFGFR2